Literature DB >> 20452135

The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.

Ayal A Aizer1, Nicole S Anderson, Steven C Oh, James B Yu, Anne M McKeon, Roy H Decker, Richard E Peschel.   

Abstract

PURPOSE: To assess the impact of pretreatment prostate volume on the development of severe acute genitourinary toxicity in patients undergoing intensity-modulated radiation therapy (IMRT) for prostate cancer. METHODS AND MATERIALS: Between 2004 and 2007, a consecutive sample of 214 patients who underwent IMRT (75.6 Gy) for prostate cancer at two referral centers was analyzed. Prostate volumes were obtained from computed tomography scans taken during treatment simulation. Genitourinary toxicity was defined using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 guidelines. Acute toxicity was defined as any toxicity originating within 90 days of the completion of radiation therapy. Patients were characterized as having a small or large prostate depending on whether their prostate volume was less than or greater than 50 cm(3), respectively. Genitourinary toxicity was compared in these groups using the chi-square or Fisher's exact test, as appropriate. Bivariate and multivariate logistic regression analysis was performed to further assess the impact of prostate volume on severe (Grade 3) acute genitourinary toxicity.
RESULTS: Patients with large prostates (>50 cm(3)) had a higher rate of acute Grade 3 genitourinary toxicity (p = .02). Prostate volume was predictive of the likelihood of developing acute Grade 3 genitourinary toxicity on bivariate (p = .004) and multivariate (p = .006) logistic regression. Every 27.0 cm(3) increase in prostate volume doubled the likelihood of acute Grade 3 genitourinary toxicity.
CONCLUSIONS: Patients with larger prostates are at higher risk for the development of severe acute genitourinary toxicity when treated with IMRT for prostate cancer. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452135     DOI: 10.1016/j.ijrobp.2009.11.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes.

Authors:  Julie C Bulman; Robert Toth; Amish D Patel; B Nicolas Bloch; Colm J McMahon; Long Ngo; Anant Madabhushi; Neil M Rofsky
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

2.  Toxicity outcome in patients treated with modulated arc radiotherapy for localized prostate cancer.

Authors:  Rafael E Lengua; Maria F Gonzalez; Kaory Barahona; Milton E Ixquiac; Juan F Lucero; Erick Montenegro; Jose L Lopez Guerra; Javier Jaén; Luis A Linares
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-24

3.  Prostate cancer: Proton therapy--revolutionary advance or diminishing returns?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

4.  Long-term quality of life outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with androgen deprivation.

Authors:  Hua-chun Luo; Li-ping Cheng; Hui-hua Cheng; Zhi-chao Fu; Shao-guang Liao; Dong-shi Li; Wen-fa Zheng; Gui-shan Lin; Jin-feng Zhu; Jian-feng Xu; Qin Yin; Qing-yang Yu
Journal:  Med Oncol       Date:  2014-05-22       Impact factor: 3.064

5.  The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.

Authors:  R Mazzola; S Fersino; A Fiorentino; F Ricchetti; N Giaj Levra; G Di Paola; G Sicignano; S Naccarato; R Ruggieri; F Alongi
Journal:  Clin Transl Oncol       Date:  2015-08-07       Impact factor: 3.405

6.  Volumetric image-guided conformal radiotherapy for localized prostate cancer: Analysis of dosimetric and clinical factors affecting acute and late toxicity.

Authors:  Gianluca Ingrosso; Alessandra Carosi; Daniela di Cristino; Elisabetta Ponti; Andrea Lancia; Marta Bottero; Alessandro Cancelli; Alessandra Murgia; Irene Turturici; Riccardo Santoni
Journal:  Rep Pract Oncol Radiother       Date:  2018-08-13

7.  Effect of pretreatment prostate volume on urinary quality of life following intensity-modulated radiation therapy for localized prostate cancer.

Authors:  Connor Chevli; Ramkishen Narayanan; Lisa Rambarran; Gregory Kubicek; K Kent Chevli; Michael Duff
Journal:  Res Rep Urol       Date:  2013-01-14

8.  Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).

Authors:  Einsley Janowski; Leonard N Chen; Joy S Kim; Siyuan Lei; Simeng Suy; Brian Collins; John Lynch; Anatoly Dritschilo; Sean Collins
Journal:  Radiat Oncol       Date:  2014-11-15       Impact factor: 3.481

Review 9.  Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy.

Authors:  Brian F Chapin
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

10.  Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer.

Authors:  Silvia Johansson; Lennart Aström; Fredrik Sandin; Ulf Isacsson; Anders Montelius; Ingela Turesson
Journal:  Prostate Cancer       Date:  2012-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.